Dezso Halbauer, MD
Psychiatry · Bradford, PANPI 1992839625
Payments from drug & device makers
Across 198 payments — averaging $12.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$928
- Alkermes, Inc.$398
- Axsome Therapeutics, Inc.$303
- Corium, LLC$154
- Supernus Pharmaceuticals, Inc.$107
- Johnson & Johnson$96
- plus $545 from 10 others
What the payments were for
- Food & beverage$2,46397%
- Education$683%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 109 | $928 |
| Alkermes, Inc. | 25 | $398 |
| Axsome Therapeutics, Inc. | 14 | $303 |
| Corium, LLC | 11 | $154 |
| Supernus Pharmaceuticals, Inc. | 6 | $107 |
| Johnson & Johnson | 5 | $96 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $87 |
| Neurocrine Biosciences, Inc. | 5 | $85 |
| Merck | 4 | $83 |
| Idorsia Pharmaceuticals US Inc | 4 | $75 |
| Lundbeck LLC | 3 | $68 |
| Indivior Inc. | 3 | $68 |
| AbbVie | 1 | $30 |
| Teva Pharmaceuticals USA, Inc. | 1 | $18 |
| Otsuka America Pharmaceutical, Inc. | 1 | $18 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
How this compares
$2,531 in reported general payments places this provider in the 85th percentile of 1,838 psychiatry providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CaplytaLumateperone Tosylate | 117 | $215,199 |
| Abilify MaintenaAripiprazole | 58 | $149,826 |
| IngrezzaValbenazine Tosylate | 15 | $119,475 |
| Invega SustennaPaliperidone Palmitate | 31 | $97,137 |
| AuvelityDextromethorphan Hbr/Bupropion | 28 | $29,962 |
| TrintellixVortioxetine Hydrobromide | 45 | $27,023 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 46 | $8,122 |
| BelsomraSuvorexant | 15 | $6,782 |
| Aripiprazole | 98 | $6,426 |
| MydayisDextroamphetamine/Amphetamine | 17 | $5,578 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 447 | $5,407 |
| Duloxetine Hcl | 223 | $2,733 |
| Clomipramine Hcl | 24 | $2,124 |
| Divalproex Sodium ErDivalproex Sodium | 78 | $2,074 |
| Fluvoxamine Maleate | 40 | $1,995 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $928 | $215,199117 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $18 | $149,82658 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $85 | $119,47515 claims |
| Johnson & JohnsonInvega Sustenna | $96 | $97,13731 claims |
| Axsome Therapeutics, Inc.Auvelity | $303 | $29,96228 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $87 | $27,02345 claims |
| MerckBelsomra | $83 | $6,78215 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,838 psychiatry providers in Pennsylvania.
Other psychiatry in Bradford
- Cherian VergheseNorristown$16.3M
- Steven ArnoldPhiladelphia$4.1M
- Paul GrossAllentown$4.1M
- Shivkumar HattiMedia$4M
- Rebecca RomaPittsburgh$3.3M
- Matthew BergerMoosic$2.4M
- Michael ThasePhiladelphia$2.2M
- Robert NelsonWyomissing$2.2M
- Mark MattaNew Castle$847K
- Mayer AyyashPittsburgh$714K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.